Skip to content

The Follow-up Study for the Patients of Illicit Substance Use Disorder

The 9-month Follow-up Study for the Patients of Illicit Substance Use Disorder After Receiving the Different Psychosocial Intervention

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04426565
Enrollment
500
Registered
2020-06-11
Start date
2020-05-01
Completion date
2022-09-30
Last updated
2020-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Illicit Drug Use, Substance Use Disorders

Brief summary

The patients will be diagnosed according to DSM-5, the severity of individual substance use disorder will be assessed, and the plan of treatment will be provided. The treatment will be determined by the diagnosis and severity of addiction, the mood or psychiatric comorbidities, the hyperactivity or attention deficit, alcohol addiction, and etc. The motivational enhancement interview, the individual psychotherapy, the group psychotherapy, the family therapy will be provided by our team members. In order to evaluate the efficacy of the different therapy, we will evaluate the psychological and social status of the patients and follow up every 3 months. The efficacy of different treatment will be evaluated according to our study instruments.

Detailed description

The patients will be diagnosed according to DSM-5, the severity of individual addiction will be assessed, and the plan of treatment will be provided. The treatment will be determined by the diagnosis and severity of addiction, the mood or psychiatric comorbidities, the hyperactivity or attention deficit, alcohol addiction, and etc. The motivational enhancement interview, the individual psychotherapy, the group psychotherapy, the family therapy will be provided by our team members. In order to evaluate the efficacy of the different therapy, we will evaluate the psychological and social status of the patients and follow up every 3 months. The patients will be received the basic physiological assessment, the chest X-ray, electrocardiogram, liver and renal function, hematology test, urine screening for addictive substances, screening for blood infectious diseases (including hepatitis B, C and HIV infection) will be included. Besides, the Drug Abuse Screen Test (DAST), the Severity of Dependence Scale (SDS), the Reliability of Readiness to Change Questionnaire, the Opiate Treatment Index (OTI), drug Avoidance Self-Efficacy Scale (DASES), the Family APGAR score, The brief version of the World Health Organization Quality of Life instrument (WHOQOL-BREF Taiwan version), Chinese health questionnaire (CHQ), parental bonding instrument (PBI), Toronto Alexithymia Scale (TAS), Brief Symptom Rating Scale (BSRS-5), Chinese version of Adult ADHD Self-Report Scale (ASRS-V1. 1), Becker Depression Scale (BDI) and Becker Anxiety Scale (BAI) will be evaluated every 3 months after receiving our treatment.

Interventions

BEHAVIORALmotivational enhancement interview

Motivational interviewing is supported by over 200 randomized controlled trials across a range of target populations and behaviors including substance abuse, health-promotion behaviors, medical adherence, and mental health issues.

BEHAVIORALthe individual psychotherapy

It has been demonstrated to be an effective treatment for depression and has been modified to treat other psychiatric disorders such as substance use disorders and eating disorders. It is incumbent upon the therapist in the treatment to quickly establish a therapeutic alliance with positive countertransference of warmth, empathy, affective attunement and positive regard for encouraging a positive transferential relationship, from which the patient is able to seek help from the therapist despite resistance.

BEHAVIORALthe group psychotherapy

Group psychotherapy is a key component of milieu therapy in a therapeutic community. The total environment or milieu is regarded as the medium of therapy, all interactions and activities regarded as potentially therapeutic and are subject to exploration and interpretation, and are explored in daily or weekly community meetings. A form of group therapy has been reported to be effective in psychotic adolescents and recovering addicts.

BEHAVIORALthe family therapy

According to a 2004 French government study conducted by French Institute of Health and Medical Research, family and couples therapy was the second most effective therapy after Cognitive behavioral therapy. The study used meta-analysis of over a hundred secondary studies to find some level of effectiveness that was either proven or presumed to exist. Of the treatments studied, family therapy was presumed or proven effective at treating schizophrenia, bipolar disorder, anorexia and substance dependence.

Sponsors

Kaohsiung Medical University
CollaboratorOTHER
Chang Gung Memorial Hospital
CollaboratorOTHER
Kaohsiung Kai-Suan Psychiatric Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

The motivational enhancement interview, the individual psychotherapy, the group psychotherapy, the family therapy will be provided by our team members.

Eligibility

Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

Patients with illicit substance use disorder diagnosed by DSM-5

Exclusion criteria

The age of the patient is below 20 years old or above 65 years old, the patients cannot cooperate with the tools of investigation

Design outcomes

Primary

MeasureTime frameDescription
The severity of substance use used by the Severity of Dependence Scale9 monthsThe value is from 0 to 15, and higher scores mean a worse outcome.
The World Health Organization Quality of Life instrument (WHOQOL-BREF Taiwan version)9 monthsThe instrument has four dimension and higher scores mean a better outcome.
Becker Depression Scale9 monthsThe value is from 0 to 63, and higher scores mean a worse outcome.
Becker Anxiety Scale9 monthsThe value is from 0 to 63, and higher scores mean a worse outcome.

Countries

Taiwan

Contacts

Primary ContactHung-Chi Wu, M.S.
wuhcmail@gmail.com+886-7-7513171
Backup ContactWei-Tsung Kao, Ph.D.
030854@gmail.com+886-7-7513171

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026